media – Page 494 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Gout Treatment – Shift from Phase 2 to Phase 3 Trial

Previous interim data reported negative results due to which the stock value of Selecta Biosciences dropped down at once by 20% in premarket trading. It was then recovered in a remarkable manner by touching the never seen before peak level.
- Source: FierceBiotech
- 515
- June 21, 2018
Clinical Trials gout
Canadian Scientists Find Blocking Certain Proteins can Avert Breast Cancer

Breast Cancer appears when unusual cells start growing in breast tissue and can affect both women and men. It was estimated that in the U.S. alone there will be a total of 330,080 new cases of breast cancer in women and about 2,550 in men by the end of 2018.
- Source: MedPageToday
- 833
- June 21, 2018
breast cancer Researches
Toothpaste Combats Lung Disease

Cystic fibrosis is the most common lung affecting genetic disease, which often turns out to be life-threatening. Nearly one in every 2500 to 3500 people are diagnosed with cystic fibrosis at an early age. A thick mucus formation in the lungs becomes stuck to bacteria, which leads to a slimy biofilm formation.
- Source: India Times
- 507
- June 21, 2018
cystic fibrosis Researches
FHIR to Support EHR Data Sharing

There are three instances of Epic along with three varied versions of Meditech, Athena health and Cerner. Lahey Health, Beth Israel Deaconess Medical Center along with three other hospitals, are currently involved in merging the organizations under one roof, as they are operating with varied EHR vendors and versions.
- Source: HealthcareIT News
- 714
- June 21, 2018
EHR FHIR Market Views
3 Foods that can fight Diabetes, Heart issues & Cancer

Proper nutrition can very well boost your overall health, by acting as your first line of defense. What are the specific nutritious foods which are more beneficial? Recent research which presented at the Nutrition 2018 conference has identified key food products in disease prevention.
- Source: Healthline
- 573
- June 21, 2018
health tips Researches
Imutex Universal FLU Vaccine Reaching Phase 3

In phase 2b clinical trial work, FLU-v met its goal of boosting T-cell immune response at 42 days and 180 days after vaccination. The infection rate came down by meeting a secondary endpoint of boosting antibodies in vaccinated patients. Thus, this single adjuvant dose is considered as the "most immunological and efficient."
- Source: FiercePharma
- 888
- June 21, 2018
Clinical Trials flu influenza vaccine
FDA Approval for AI Enabled Diabetes Software

The Food and Drug Administration (FDA) has granted approval for a request made by DreaMed regarding their artificial intelligence-enabled diabetic software, which is exclusively meant for the providers, who are managing Type 1 diabetes patients.
- Source: MobiHealthNews
- 859
- June 20, 2018
AI digital health FDA New Approvals type 1 diabetes
Salmonella Warning for Cut Melons

Fresh cut melons sold at popular grocery stores were responsible for nearly 60 people being infected with Salmonella. In order to be sure of what is safe to consume and what not, refer to the list of Food and Drug Administration (FDA) consumable items. Here they state that people need not give up melons entirely but rather only the pre-cut ones.
- Source: HealthLine
- 551
- June 20, 2018
Researches Salmonella
Vertex Pharma Doubles Cystic Fibrosis Research Facility

Boston-based Vertex Pharmaceuticals has more than doubled their research facility in San Diego where they first discovered their key Cystic Fibrosis Drug adding more than 90000 sq ft. to it. The total facility will be now 170,000 sq. ft improving the pharma giant's capability to achieve the next generation of blockbusters.
- Source: Fierce Biotech
- 602
- June 20, 2018
biotech Company Insights
Syncona Once More Proves Commitment to Freeline in Series B Funding Round

Syncona has once again proven its commitment to gene therapy start-up, Freeline Therapeutics with a £85 million investment from the £88 million series B funding round. Freeline’s main focus is on gene therapy for Haemophilia B and Farby disease and this latest cash injection ensures Syncosa’s majority stake in the startup.
- Source: Fierce Biotech
- 649
- June 20, 2018
biotech Company Insight funding hemophilia

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.